Literature DB >> 19214773

Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease.

S Decarlis1, C Agostoni, F Ferrante, S Scarlino, E Riva, M Giovannini.   

Abstract

Lysosomal acid lipase (LAL) deficiency results in Wolman disease and cholesteryl ester storage disease (CESD), a more benign form. CESD is a recessive disorder characterized by hypercholesterolaemia, hypertriglyceridaemia, low blood HDL and variable phenotype, while hepatomegaly is usually evident during childhood or adolescence. An 11-year-old girl was referred to our department for combined hyperlipidaemia (total cholesterol 323, triglycerides 259 mg/dl). All family members had normal lipid profile and liver function tests. At 8 years she was admitted for acute Epstein-Barr virus infection, with hepatosplenomegaly and elevation of liver enzymes. Liver-spleen enlargement resolved, but serum alanine aminotransferase and aspartate aminotransferase were persistently twice the upper limits, with other liver function tests within the normal range. Ultrasonography showed normal liver and spleen size and minimal hepatic steatosis. Infectious, autoimmune and metabolic causes of elevated liver enzymes were ruled out, including glycogen storage disease. Dysbetalipoproteinaemia was also ruled out (ApoE phenotype: E3E3). In the following 2 years the girl was symptom-free, BMI was at the 50th-75th centile for age and lipid profile was unchanged despite a low-fat diet. At 13 years of age, low acid lipase activity was demonstrated in leukocytes (10 nmol/h/ per mg protein, normal 140-380) and cultured skin fibroblasts (181 nmol/h per mg protein, normal 1100-2400), leading to diagnosis of CESD. CESD usually progresses to hepatic fibrosis, with high risk of premature atherosclerosis. CESD prevalence may be underestimated in the general population. The diagnosis may be considered in all subjects with atypical combined hyperlipidaemia (usually dominant in transmission or related to metabolic syndrome) and atypical 'fatty liver disease', in the absence of overweight.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214773     DOI: 10.1007/s10545-008-1027-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  8 in total

1.  Prevalence of cholesteryl ester storage disease.

Authors:  Sandro Muntoni; Heiko Wiebusch; Marianne Jansen-Rust; Stephan Rust; Udo Seedorf; Helmut Schulte; Klaus Berger; Harald Funke; Gerd Assmann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08       Impact factor: 8.311

2.  Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer.

Authors:  M Elleder; A Chlumská; J Hyánek; H Poupĕtová; J Ledvinová; S Maas; P Lohse
Journal:  J Hepatol       Date:  2000-03       Impact factor: 25.083

3.  Expression of lysosomal acid lipase mutants detected in three patients with cholesteryl ester storage disease.

Authors:  F Pagani; R Garcia; R Pariyarath; C Stuani; B Gridelli; G Paone; F E Baralle
Journal:  Hum Mol Genet       Date:  1996-10       Impact factor: 6.150

4.  Homozygosity for a splice junction mutation in exon 8 of the gene encoding lysosomal acid lipase in a Spanish kindred with cholesterol ester storage disease (CESD).

Authors:  S Muntoni; H Wiebusch; H Funke; E Ros; U Seedorf; G Assmann
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

5.  Lysosomal acid lipase in cultivated fibroblasts: characterization of enzyme activity in normal and enzymatically deficient cell lines.

Authors:  B K Burton; D Emery; H W Mueller
Journal:  Clin Chim Acta       Date:  1980-02-14       Impact factor: 3.786

6.  Lysosomal acid lipase mutations that determine phenotype in Wolman and cholesterol ester storage disease.

Authors:  R A Anderson; G M Bryson; J S Parks
Journal:  Mol Genet Metab       Date:  1999-11       Impact factor: 4.797

7.  The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy.

Authors:  Hong Du; Mark Levine; Chandrashekar Ganesa; David P Witte; Edward S Cole; Gregory A Grabowski
Journal:  Am J Hum Genet       Date:  2005-10-27       Impact factor: 11.025

8.  Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.

Authors:  Venu T Tadiboyina; Dora M Liu; Brooke A Miskie; Jian Wang; Robert A Hegele
Journal:  Lipids Health Dis       Date:  2005-10-28       Impact factor: 3.876

  8 in total
  5 in total

Review 1.  Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.

Authors:  Tyler J Severson; Siddesh Besur; Herbert L Bonkovsky
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 2.  Genetic determinants of hepatic steatosis in man.

Authors:  Amanda J Hooper; Leon A Adams; John R Burnett
Journal:  J Lipid Res       Date:  2011-01-18       Impact factor: 5.922

3.  A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease.

Authors:  S J Cameron; U Daimee; R C Block
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015       Impact factor: 3.507

Review 4.  Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa.

Authors:  Kim Su; Emma Donaldson; Reena Sharma
Journal:  Appl Clin Genet       Date:  2016-10-17

Review 5.  Lysosomal acid lipase deficiency in pediatric patients: a scoping review.

Authors:  Camila da Rosa Witeck; Anne Calbusch Schmitz; Júlia Meller Dias de Oliveira; André Luís Porporatti; Graziela De Luca Canto; Maria Marlene de Souza Pires
Journal:  J Pediatr (Rio J)       Date:  2021-05-06       Impact factor: 2.990

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.